Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomyYuta Yamada, Haruki Kume, Yoichi Fujii et al.|Scientific Reports|2024Cited by 4
Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Haruki Kume, H Hoshina et al.|International Journal of Urology|2024Cited by 4
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Haruki Kume, Taketo Kawai et al.|Research Square|2024Cited by 2
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world studyIbuki Tsuru, Haruki Kume, Satoru Taguchi et al.|Japanese Journal of Clinical Oncology|2026Cited by 0